# A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07124117/  
OnCo record `nct07124117` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of OBI-902 in advanced solid tumours, run by OBI Pharma, Inc, now recruiting.

## Summary

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07124117 by OBI Pharma, Inc, with 147 participants planned, started 2025-08-04 and due to reach its primary completion in 2029-02-08. Interventions recorded: OBI-902.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07124117
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-902 in Participants With Advanced Solid Tumors
- Sponsor: OBI Pharma, Inc
- Enrolled: 147

## Sources

- ClinicalTrials.gov NCT07124117: https://clinicaltrials.gov/study/NCT07124117

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [OBI-902](https://onco.cc/drugs/obi-902/)

---
JSON: https://onco.cc/api/v1/entities/nct07124117.json